[go: up one dir, main page]

FR3088824B1 - LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES - Google Patents

LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES Download PDF

Info

Publication number
FR3088824B1
FR3088824B1 FR1872020A FR1872020A FR3088824B1 FR 3088824 B1 FR3088824 B1 FR 3088824B1 FR 1872020 A FR1872020 A FR 1872020A FR 1872020 A FR1872020 A FR 1872020A FR 3088824 B1 FR3088824 B1 FR 3088824B1
Authority
FR
France
Prior art keywords
molecular weight
low molecular
fucanes
sulphates
inflammatory dermatoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1872020A
Other languages
French (fr)
Other versions
FR3088824A1 (en
Inventor
Marie Françoise Aries
Stéphane Poigny
Hélène Hernandez-Pigeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Priority to FR1872020A priority Critical patent/FR3088824B1/en
Priority to PCT/EP2019/082861 priority patent/WO2020109445A1/en
Publication of FR3088824A1 publication Critical patent/FR3088824A1/en
Application granted granted Critical
Publication of FR3088824B1 publication Critical patent/FR3088824B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l’utilisation d’un fucane sulfaté de bas poids moléculaire (1-25kDa), ainsi que d’une composition dermatologique ou dermo-cosmétique contenant un tel fucane, dans le traitement et/ou la prévention de dermatoses inflammatoires, notamment la dermatite atopique.The present invention relates to the use of a sulfated fucan of low molecular weight (1-25 kDa), as well as of a dermatological or dermo-cosmetic composition containing such a fucan, in the treatment and / or prevention of inflammatory dermatoses, especially atopic dermatitis.

FR1872020A 2018-11-28 2018-11-28 LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES Expired - Fee Related FR3088824B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1872020A FR3088824B1 (en) 2018-11-28 2018-11-28 LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES
PCT/EP2019/082861 WO2020109445A1 (en) 2018-11-28 2019-11-28 Low molecular weight sulphated fucans in the treatment of atopic dermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1872020A FR3088824B1 (en) 2018-11-28 2018-11-28 LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES

Publications (2)

Publication Number Publication Date
FR3088824A1 FR3088824A1 (en) 2020-05-29
FR3088824B1 true FR3088824B1 (en) 2021-01-15

Family

ID=66542321

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1872020A Expired - Fee Related FR3088824B1 (en) 2018-11-28 2018-11-28 LOW MOLECULAR WEIGHT SULPHATES FUCANES IN INFLAMMATORY DERMATOSES

Country Status (2)

Country Link
FR (1) FR3088824B1 (en)
WO (1) WO2020109445A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426381B2 (en) * 2005-09-09 2013-04-23 Lucas Meyer Cosmetics Canada Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
WO2010086696A1 (en) 2009-01-28 2010-08-05 Therapol Low-molecular-weight sulphated polysaccharides as candidates for anti-angiogenic therapy

Also Published As

Publication number Publication date
WO2020109445A1 (en) 2020-06-04
FR3088824A1 (en) 2020-05-29

Similar Documents

Publication Publication Date Title
PH12019500862A1 (en) Novel cd47 monoclonal antibodies and uses thereof
CR20200114A (en) Pyrazolopyrimidinone compounds and uses thereof
MA55434A (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
BR112017022021A2 (en) application of surfactant soluble anti-dandruff agent
MA43187B1 (en) Subcutaneous anti-cd38 antibody formulations and their uses
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
BR112016008409A2 (en) USE OF A MASP-2 INHIBITORY AGENT THAT INHIBITS MASP-2 DEPENDENT COMPLEMENT ACTIVATION
MA39767B1 (en) Ophthalmic aqueous solution and dry eye syndrome treatment method
EA202091230A3 (en) ANTAGONISTS OF ACTIVIN-ACTRII AND THEIR APPLICATION FOR INCREASING THE LEVELS OF ERYTHROCYTES
MA35844B1 (en) Pyrimidines and substituted ringed triazines and their use
MA41010A (en) COMPOSITIONS INCLUDING BACTERIAL STRAINS
MA39250A1 (en) Hybrid Proteins of Interleukin-2 and Their Uses
MX2018000447A (en) Novel proteins specific for lag-3.
TW200622349A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
FR3028753B1 (en) AQUEOUS OR HYDRO-ALCOHOLIC GEL OF SYNTHETIC PHYLLOSILICATES AS A VISCOSING AGENT, MATIFIING AND / OR HOMOGENIZING APPLICATION
MD4685B1 (en) Method of treatment of conditions associated with complement activation dependent on MASP-2
SA520411871B1 (en) Antibody Variant and Isoform With Lowered Biological Activity
MA40283A (en) TLR-4 RECEIVER SPECIFIC APTAMERS AND THEIR USES
CL2021000650A1 (en) Modulators of pnpla3 expression
MX2019008434A (en) Lipocalin muteins with binding affinity for lag-3.
BR112016013800A2 (en) COMPOSITIONS AND METHODS TO REDUCE CAT ALLERGENS IN THE ENVIRONMENT
MX2022008659A (en) Antibody molecules to c5ar1 and uses thereof.
FR3065644B1 (en) PHARMACEUTICAL QUALITY 20-HYDROXYECDYSONE EXTRACT, ITS USE AND ITS PREPARATION
FR3075037B1 (en) COMBINATION OF A RETINOIDE AND AN EXTRACT OF SILYBUM MARIANUM (L.) GAERTN
MA38369A1 (en) Peptides and compositions for the treatment of a lesion of the joint

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200529

PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20220705